Tempus AI reported strong Q3 2026 financial results, exceeding analyst expectations for EPS and demonstrating robust growth in key segments. The company also raised its full-year revenue guidance, indicating positive momentum and potentially leading to an upward revision of analyst forecasts.
Tempus AI announced impressive Q3 2026 financial results, with reported adjusted EPS of $0.07 significantly surpassing analyst expectations of a $0.09 loss per share. This strong performance was driven by 32% unit growth in its oncology business and 33% revenue growth in its Data & Applications segment. The company further bolstered investor confidence by raising its full-year 2026 revenue guidance to a range of $1.6 billion to $1.61 billion. This news is a major positive catalyst for Tempus AI, indicating strong operational execution and potentially leading to a re-rating of the stock by investors and analysts. The short-term implication is likely a positive stock price movement, while long-term investors will see this as validation of the company's growth strategy in the healthcare technology sector.